Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenues:
Clinical treatment programs	$ 23	$ 45	$ 106	$ 157
Total revenues	23	45	106	157
Costs and expenses:
Production	353	306	1,232	923
Research and development	1,968	1,894	7,081	6,550
General and administrative	1,685	2,174	5,600	7,210
Total costs and expenses	4,006	4,374	13,913	14,683
Operating loss	(3,983)	(4,329)	(13,807)	(14,526)
Interest expense	(1)	(3)	(3)	(9)
Interest and other income/expense	181	130	343	414
Redeemable warrants valuation adjustment	0	0	0	1
Gain from sale of income tax net operating losses	0	0	1,374	1,126
Net loss	(3,803)	(4,202)	(12,093)	(12,994)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	(215)	(169)	(241)	0
Net comprehensive loss	$ (4,018)	$ (4,371)	$ (12,334)	$ (12,994)
Basic and diluted loss per share (usd per share)	$ (0.02)	$ (0.02)	$ (0.05)	$ (0.07)
Weighted average shares outstanding, basic and diluted (shares)	246,774,460	190,677,576	232,307,548	184,434,475